Key result
Pretreatment with ACEI or ARBs did not reduce the recurrence rate of atrial fibrillation after pulmonary vein isolation, and was instead associated with an increased risk of recurrence (HR 1.58).
Why the study?
Does pretreatment with ACEI or ARBs reduce AF recurrence in patients with paroxysmal or persistent AF undergoing ablation?
Cohort (n=312)
No
Does pretreatment with ACEI or ARBs reduce AF recurrence in patients with paroxysmal or persistent AF undergoing ablation?
Hazard Ratio: 1.58 (95% CI 1.05–2.39)
Absolute Event Rate: 39% vs 25%
p-value: p=0.028
Pretreatment with ACEI or ARBs is not associated with a reduced recurrence rate of atrial fibrillation after pulmonary vein isolation.
Pretreatment with ACEI or ARBs is not associated with reduced recurrence rate in patients with paroxysmal or persistent AF undergoing ablation.
No takes yet. Share an insight, caveat, or question.
Rosen et al. (2013) conducted a cohort in Paroxysmal and Persistent Atrial Fibrillation (n=312). Renin Angiotensin Blockers (ACEI or ARBs) vs. No ACEI or ARB treatment was evaluated on Atrial fibrillation recurrence (HR 1.58, 95% CI 1.05-2.39, p=0.028). Pretreatment with ACEI or ARBs did not reduce the recurrence rate of atrial fibrillation after pulmonary vein isolation, and was instead associated with an increased risk of recurrence (HR 1.58).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: